Mesoblast

US · MESO #2849 by market cap Listed 2015

13.94 +0.33 +2.42%

Live - 5344 symbols - heartbeat 108s ago · 2026-10-08 08:34

Pre-market 13.61 -2.37%

After-hours 13.90 -0.29%

Overnight 13.48 -3.30%

Market cap: 1.81B
P/E (TTM): -31.68
P/B: 3.19
EPS: -0.44
Div yield: 0.00%
52W pos: 11%

Reader sentiment Are you bullish or bearish on MESO?

Anonymous reader poll. Unscientific, not investment advice.

About Mesoblast

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Founded: 2004
CEO: Dr. Silviu Itescu, F.A.C.P.,F.R.A.C.P.
Employees: 108
Headquarters: Melbourne, Victoria (VIC), Australia
Fiscal year end: 06-30
Website: mesoblast.com

Company profile

Exchange: US
Symbol: MESO
Market-cap rank: #2849
Listing date: 2015-11-13
Market cap: 1.81B
Float cap: 1.20B
Shares out: 130.08M
Float shares: 86.19M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:34:10 · For reference only, not investment advice and not tailored to your situation.